Literature DB >> 11224569

Predicting the emergence of antibiotic resistance by directed evolution and structural analysis.

M C Orencia1, J S Yoon, J E Ness, W P Stemmer, R C Stevens.   

Abstract

Directed evolution can be a powerful tool to predict antibiotic resistance. Resistance involves the accumulation of mutations beneficial to the pathogen while maintaining residue interactions and core packing that are critical for preserving function. The constraint of maintaining stability, while increasing activity, drastically reduces the number of possible mutational combination pathways. To test this theory, TEM-1 beta-lactamase was evolved using a hypermutator E. coli-based directed evolution technique with cefotaxime selection. The selected mutants were compared to two previous directed evolution studies and a database of clinical isolates. In all cases, evolution resulted in the generation of the E104K/M182T/G238S combination of mutations ( approximately 500-fold increased resistance), which is equivalent to clinical isolate TEM-52. The structure of TEM-52 was determined to 2.4 A. G238S widens access to the active site by 2.8 A whereas E104K stabilizes the reorganized topology. The M182T mutation is located 17 A from the active site and appears to be a global suppressor mutation that acts to stabilize the new enzyme structure. Our results demonstrate that directed evolution coupled with structural analysis can be used to predict future mutations that lead to increased antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11224569     DOI: 10.1038/84981

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  94 in total

1.  Mutator bacteria as a risk factor in treatment of infectious diseases.

Authors:  Antoine Giraud; Ivan Matic; Miroslav Radman; Michel Fons; François Taddei
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2002-03       Impact factor: 4.562

3.  Predicting evolution by in vitro evolution requires determining evolutionary pathways.

Authors:  Barry G Hall
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

4.  Evolutionary potential of an RNA virus.

Authors:  Eugene V Makeyev; Dennis H Bamford
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  Combining computational and experimental screening for rapid optimization of protein properties.

Authors:  Robert J Hayes; Jorg Bentzien; Marie L Ary; Marian Y Hwang; Jonathan M Jacinto; Jöst Vielmetter; Anirban Kundu; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-21       Impact factor: 11.205

6.  SHV-129: A Gateway to Global Suppressors in the SHV β-Lactamase Family?

Authors:  Marisa L Winkler; Robert A Bonomo
Journal:  Mol Biol Evol       Date:  2015-11-03       Impact factor: 16.240

7.  High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognition.

Authors:  Pierre-Yves De Wals; Nicolas Doucet; Joelle N Pelletier
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

8.  Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.

Authors:  Philippe Egesborg; Hélène Carlettini; Jordan P Volpato; Nicolas Doucet
Journal:  Protein Sci       Date:  2014-12-30       Impact factor: 6.725

Review 9.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

10.  Characterization and crystal structure of Escherichia coli KDPGal aldolase.

Authors:  Matthew J Walters; Velupillai Srikannathasan; Andrew R McEwan; James H Naismith; Carol A Fierke; Eric J Toone
Journal:  Bioorg Med Chem       Date:  2007-10-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.